ArticleJournal of controlled release : official journal of the Controlled Release Society2007
Inhibition of transferrin iron release increases in vitro drug carrier efficacy.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- Dual Chemotherapeutic Loading in Oxalate Transferrin-Conjugated Polymersomes Incorporated into Chitosan Hydrogels for Site-Specific Targeting of Melanoma Cells.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Transferrin-Conjugated PLGA Nanoparticles for Co-Delivery of Temozolomide and Bortezomib to Glioblastoma Cells.ACS applied nano materials · 2023Article
- Modeling cell-specific dynamics and regulation of the common gamma chain cytokines.Cell reports · 2021Article
- Mathematical modeling of mutant transferrin-CRM107 molecular conjugates for cancer therapy.Journal of theoretical biology · 2017Article
- Engineering an Anti-Transferrin Receptor ScFv for pH-Sensitive Binding Leads to Increased Intracellular Accumulation.PloS one · 2015Article
- Yeast Display-Based Antibody Affinity Maturation Using Detergent-Solubilized Cell Lysates.Methods in molecular biology (Clifton, N.J.) · 2015Article
- Mass spectrometry-guided optimization and characterization of a biologically active transferrin-lysozyme model drug conjugate.Molecular pharmaceutics · 2013Article
- Cells and cell lysates: a direct approach for engineering antibodies against membrane proteins using yeast surface display.Methods (San Diego, Calif.) · 2013Review
- Strategies for overcoming the blood-brain barrier for the treatment of brain metastases.CNS oncology · 2013Review
- The intracellular trafficking pathway of transferrin.Biochimica et biophysica acta · 2012Review
- Intracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer.Annals of biomedical engineering · 2011Review
- Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery.Cancer research · 2010Article
- Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins.Journal of controlled release : official journal of the Controlled Release Society · 2009Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Transferrin (Tf) conjugates of CRM107 are currently being tested in clinical trials for treatment of malignant gliomas. However, the rapid cellular recycling of Tf limits its efficiency as a drug carrier. We have developed a mathematical model of the Tf/TfR trafficking cycle and have identified the Tf iron release rate as a previously unreported factor governing the degree of Tf cellular association. The release of iron from Tf is inhibited by replacing the synergistic carbonate anion with oxalate. Trafficking patterns for oxalate Tf and native Tf are compared by measuring their cellular association with HeLa cells. The amount of Tf associated with the cells is an average of 51% greater for oxalate Tf than for native Tf over a two hour period at Tf concentrations of 0.1 nM and 1 nM. Importantly, diphtheria toxin (DT) conjugates of oxalate Tf are more cytotoxic against HeLa cells than conjugates of native Tf. Conjugate IC(50) values were determined to be 0.06 nM for the oxalate Tf conjugate vs. 0.22 nM for the native Tf conjugate. Thus, we show that inhibition of Tf iron release improves the efficacy of Tf as a drug carrier through increased association with cells expressing TfR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.